Up­dat­ed: Sam­sara backs ex-Gilead duo's amal­ga­ma­tion of NASH, liv­er drug as­sets from for­mer em­ploy­er, oth­er bio­phar­mas

A new biotech just dropped with a bas­ket of as­sets, in­clud­ing two clin­i­cal-stage ones, from Gilead, Sh­iono­gi, Phenex Phar­ma­ceu­ti­cals, Astel­las’ Mi­to­bridge and Yale.

The Pa­lo Al­to up­start is look­ing to treat se­vere meta­bol­ic dis­or­ders, such as NASH and type 2 di­a­betes. Lead­ing the com­pa­ny is Mani Sub­ra­man­ian, who head­ed up liv­er dis­ease ther­a­peu­tic de­vel­op­ment at Gilead un­til 2020. Sam­sara Bio­Cap­i­tal, where Sub­ra­man­ian is a ven­ture part­ner, helped in­cu­bate the com­pa­ny, Or­so­Bio an­nounced Tues­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER